Clinical Trial Search

Primary: Fasting F-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) Imaging Complete Metabolic Response, Reported Following National Cancer Institute (NCI) and…

Primary: Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks) — 0.3; 0.9 g/dL — p=.0062

Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery — 24 Participants

Primary: Proportion of Patients Alive and Without Progression of Disease at 1 Year From Start of Protocol-based Therapy. — 36; 29 percentage of participants

Primary: Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population. — 8; 44 percentage of participants

Primary: Change in Breast Milk Volume Baseline to 7 Days — -12; 429; 44 % change from baseline

Primary: Apathy Evaluation Scale (AES) — -1.9; 0.6 units on a scale

Primary: Time to Progression of Disease or Death — 7.9; 5.8 Months

Primary: Toxicity. Number of Patients With Specific Toxicities Are Reported. — 90; 79 percentage of patients

Primary: Estimate of the 6 Month Survival Probability — 49.4; 44.1 Percent chance of survival — p=>0.05

Primary: Breast Milk Production — 66.1 mL/day

Primary: Objective Response Rates. Assessed With Cranial MRI — 78.6; 48.1 Percentage of participants with OR — p=0.019

Primary: Net Change Relative to Baseline in Tumor Blood Flow — -0.44; -0.12; -0.60; -0.40 ml/min/100gm

Primary: Brachial Artery Flow-mediated Dilation (FMD) — 12.0; 9.8; 10.4; 10.2 % change in brachial artery diameter — p=0.58

Primary: Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response…